A bad day for Molecular Partners
Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.
JP Morgan 2022 – day one sees healthy deal flow from biopharma
But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
Atea’s woes grow while other Covid readouts approach
Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.
Amgen doubles down on bispecifics, courtesy of Teneobio
Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
US appetite for Covid-19 treatments remains undiminished
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Merck’s Covid-19 push narrows further
Merck & Co gives up on MK-7110, and on molnupiravir in hospitalised patients.
Molnupiravir’s big day draws near
Early data whet appetites ahead of the big event for one of the few remaining antiviral hopes in Covid-19.
